KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally reverse the biology of aging skin, announced today positive safety and efficacy results, including significant im ...

EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced podium presentations at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Long Beach, CA, from July 30 – August 2, 2025. ASRS 2025 Prese ...

SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on bu ...

LOS ALTOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the publication of pivotal trial data describing the safety and tolerability of oxylanthanum carbonate (OLC) in chronic kidney disease (CKD) patients on dialysis in the Clinical Journal of the American Society of Nephrology. The publication, entitled “A Phase 2 Clinical Tr ...

Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine PlatformTechnology Addresses Substantial Unmet Need in Preventive Oncology with Multi-Billion Dollar Market PotentialSAN JOSE, Calif., July 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,370,244 on July 29, 2025, cove ...

收购交易核心条款 - 礼来公司以每股10.50美元现金加最高3美元或有价值权(CVR)的条件收购Verve Therapeutics全部流通股 [1] - 交易包含非交易型或有价值权(CVR)，该权利在达到特定里程碑时支付 [1] - 要约于2025年7月23日美国东部时间23:59到期未延期 [1] 交易执行情况 - 截至到期时间共49,882,464股(占流通股55.7%)被有效投标且未撤回 [2] - 礼来及其全资子公司Ridgeway Acquisition Corporation已接受所有有效投标股份并将及时支付 [2] - 交易预计于2025年7月25日完成 [3] 交易相关方 - 礼来法律顾问为Kirkland & Ellis LLP [3] - Verve财务顾问为Centerview Partners LLC和Guggenheim Securities LLC [3] - Verve法律顾问为Paul, Weiss, Rifkind, Wharton & Garrison LLP [3] Verve Therapeutics业务概况 - 临床阶段基因编辑公司，专注于心血管疾病治疗 [4] - 主要开发单疗程基因编辑药物替代现有慢性疗法 [4] - 三大核心项目分别靶向导致动脉粥样硬化的三种脂蛋白 [4] - VERVE-102靶向PCSK9基因，用于家族性高胆固醇血症和动脉粥样硬化心血管疾病 [4] - VERVE-201靶向ANGPTL3基因，用于难治性高胆固醇血症 [4] - VERVE-301靶向LPA基因，降低脂蛋白(a)水平 [4] 礼来公司业务概况 - 拥有近150年历史的跨国制药企业 [5] - 专注糖尿病、肥胖症、阿尔茨海默病、免疫系统疾病和癌症治疗领域 [5] - 通过生物技术、化学和基因医学推动新药研发 [5]

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, development and commercial milestonesMatchpoint will lead all research activities through development candidate selection WATERTOWN, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Matchpoint Therapeutics, a biotechnology company pioneering the discovery of precision covalent medicines, today announced that it has entered into an exclusive option and lic ...

TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding creativity and talent among early-career scientists in biomedical research. Each year, top U.S. research universities nominate their most promising graduate students and postdoctoral fellows for this honor. These nominees are invited to develop and pitch their ...

– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy – MELBOURNE, Australia and SAN FRANCISCO, July 24, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an innovative neuroimaging ...

Should you invest in stocks right now? Some might be hesitant to do so because of the volatility broader equities have faced this year. Others understand that the stock market generates excellent returns over the long run, regardless of short-term uncertainty. I firmly belong to the second camp. The key is to invest in companies that are likely to deliver strong financial results and returns over five years or more. For those who, like me, are still seeking quality stocks to invest in, let's consider two co ...